Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 17/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3914422 | 0.89 | DRD2 (1.00) | DRD2 | |
| SCHEMBL3915782 | 0.89 | DRD2 (1.00) | DRD2 | |
| SCHEMBL3914096 | 0.85 | DRD2 (1.00) | DRD2 | |
| SCHEMBL3922357 | 0.83 | DRD2 (1.00) | DRD2 | |
| SCHEMBL9369575 | 0.82 | DRD2 (1.00) | DRD2 | |
| SCHEMBL3912648 | 0.82 | DRD2 (1.00) | DRD2 | |
| SCHEMBL3924405 | 0.79 | DRD2 (1.00) | DRD2 | |
| SCHEMBL3914302 | 0.79 | DRD2 (1.00) | DRD2 | |
| SCHEMBL3923281 | 0.79 | DRD2 (1.00) | DRD2 | |
| SCHEMBL3913948 | 0.79 | DRD2 (1.00) | DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1824486-B1 | BENZDIOXANE PIPERAZINE DERIVATIVES WITH A COMBINATION OF AFFINITY FOR DOPAMINE-D2 RECEPTORS AND SEROTONIN REUPTAKE SITES | SOLVAY PHARM BV (NL) | 2009-03-18 | — | — | EP | disclosed |
| US-20060122175-A1 | Benzdioxane piperazine derivatives with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites | SOLVAY PHARMACEUTICALS B.V. | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122175-A1 | Benzdioxane piperazine derivatives with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites | HTR2C, HTR2A, DRD2 | DRD2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.